Why We Check These Antibodies in ILD
We check ANA, anti-Scl-70, anti-ENA antibodies, and aldolase in ILD patients primarily to identify underlying systemic autoimmune rheumatic diseases (SARDs), which are critical risk factors for ILD development and significantly impact prognosis, treatment decisions, and mortality. These tests help distinguish connective tissue disease-associated ILD (CTD-ILD) from idiopathic forms, as CTD-ILD affects over 50% of certain SARD patients and represents a leading cause of death in these populations 1.
The Diagnostic Framework
ANA (Antinuclear Antibody)
- Primary screening tool for underlying autoimmune disease in ILD patients
- ANA positivity occurs in 32% of ILD patients, with 42% of ANA-positive patients ultimately diagnosed with CTD versus only 8% of ANA-negative patients 2
- High-titer ANA (≥1:320) is particularly predictive of CTD diagnosis (OR=14.4) 2
- In autoimmune-featured ILD, ANA titers ≥1:1280 are associated with improved survival 3
- Nucleolar pattern on immunofluorescence is significantly more prevalent in CTD-ILD (11.1%) and specifically suggests systemic sclerosis 4
Anti-Scl-70 (Anti-Topoisomerase I)
- Highly specific for systemic sclerosis-associated ILD
- Listed as a major risk factor for ILD development in SSc patients 1
- Part of the three-antibody operational rule (anti-Ro52, anti-SS-A, anti-Scl-70) that captures 68.3% of CTD-ILD cases 5
- Contributes 7.0% population attributable fraction for CTD-ILD 5
Anti-ENA Antibodies (Extractable Nuclear Antigens)
The 2014 international recommendations explicitly state: "In case of high clinical suspicion the physician request for determination of antibodies to specific ENA should be granted, irrespective of the result of the ANA test" 6. This is crucial because:
- Anti-Jo-1 (and other anti-synthetase antibodies): Major risk factor for ILD in idiopathic inflammatory myopathies 1
- Anti-SS-A/Ro and Anti-Ro52: Significantly elevated in CTD-ILD, with anti-Ro52 showing adjusted OR of 3.21 and contributing 35.5% population attributable fraction 5, 4
- Anti-RNP: Elevated in lupus-ILD and required for mixed connective tissue disease diagnosis 4
- Anti-MDA5: Significantly elevated in CTD-ILD (p=0.001) and identified as a predictor of ILD in inflammatory myopathies 4, 7
Critical caveat: Some patients with specific ENA antibodies (Jo-1, ribosomal P, SS-A/Ro) may be ANA-negative by indirect immunofluorescence, making direct ENA testing essential when clinical suspicion is high 6.
Aldolase
- Muscle enzyme marker for inflammatory myopathies
- Idiopathic inflammatory myopathies are at particularly high risk for ILD, with anti-synthetase antibodies being major risk factors 1
- Used alongside other muscle enzymes to identify myositis, which has strong ILD associations
What About ACE?
ACE (angiotensin-converting enzyme) is NOT recommended for routine ILD screening or monitoring based on the 2023 ACR/CHEST guidelines [1-1. While historically used for sarcoidosis, the evidence shows:
- ACE is elevated in sarcoidosis, silicosis, and miliary tuberculosis but normal in most other ILDs including COPD, interstitial pulmonary fibrosis, and cavitary tuberculosis 8
- Single ACE measurements do not predict presence, extent, or prognosis of lung injury 9
- Serial decreasing ACE levels are associated with high mortality but this is not part of standard ILD evaluation 9
- ACE testing is specific to granulomatous diseases, not the broader ILD evaluation for autoimmune causes
Clinical Algorithm
When evaluating ILD, order these tests to:
- Screen for underlying SARD - Start with ANA as the broad screening test
- If ANA positive (especially ≥1:320) - Proceed to specific ENA panel including anti-Scl-70, anti-SS-A, anti-Ro52, anti-RNP, anti-Jo-1, and anti-MDA5
- If clinical features suggest myositis (weakness, rash, mechanic's hands) - Check aldolase and anti-synthetase antibodies even if ANA is negative
- If clinical features suggest SSc (Raynaud's, skin thickening) - Ensure anti-Scl-70 is checked even if ANA is negative
The 2023 ACR/CHEST guidelines emphasize that identifying CTD-ILD is critical because it fundamentally changes management, prognosis, and requires co-management between rheumatology and pulmonology [1-1. These antibody tests are not for monitoring ILD progression (use PFTs and HRCT for that), but for establishing the underlying etiology which directly impacts mortality and treatment approach.